ASND
Ascendis Pharma A/S
NASDAQ · Healthcare · Biotechnology · DK
$270.56
−0.21%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
37.3x
EV/EBITDA
190.8x
Market Cap
$17.75B
MomentumView details →
1D Return
−0.21%
YTD Return
+25.57%
RSI (14)
61.6
ValuationView details →
P/E (Fwd)
37.3x
EV/EBITDA
190.8x
Market Cap
$17.75B
RSI (14)
61.6
MomentumView details →
1D Return
−0.21%
YTD Return
+25.57%
SummaryUpdated Jun 1, 2026
Ascendis Pharma A/S (NASDAQ:ASND) is a Danish biopharmaceutical company founded in 2006 and headquartered in Hellerup, Denmark. The company went public on NASDAQ in January 2015. Ascendis specializes in developing innovative therapeutics for rare endocrine diseases using its proprietary TransCon technology platform, which enables the creation of long-acting versions of existing drugs. The company has successfully commercialized two products and maintains a robust pipeline of treatments targeting unmet medical needs in endocrinology and oncology.
Similar companies
Latest newsMore news →
BioMarin Pharmaceutical signed a binding term sheet with Ascendis Pharma for a global settlement and license agreement, granting Ascendis a non-exclusive, worldwide, royalty-bearing license to certain BioMarin patents for products including TransCon CNP, navepegritide, or Yuviwel, with all pending litigation to be dismissed with prejudice.4d agoAscendis Pharma reported its second quarter 2026 financial results, with product revenue of €315 million, up 105% year-over-year.22d ago